MTOR and liver disorder: Previous studies provided some insights into the regulation mechanisms of GP73 expression via activation of the mammalian target of rapamycin (mTOR) pathway and inflammation-related factors such as Interleukin-6 (IL-6) in liver disease [35,36,37,38].